covid
Buscar en
Revista Médica Internacional sobre el Síndrome de Down (English Edition)
Toda la web
Inicio Revista Médica Internacional sobre el Síndrome de Down (English Edition) Immunizable diseases and Down syndrome
Información de la revista
Vol. 12. Núm. 2.
Páginas 18-24 (julio 2008)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 12. Núm. 2.
Páginas 18-24 (julio 2008)
Acceso a texto completo
Immunizable diseases and Down syndrome
Visitas
1021
Josep Ma Corretger Rauet
Medical director of the Down Medical Center (Centre Mèdic Down -CMD) at Fundació Catalana Síndrome de Down. Member of the Government of Catalonia's Advisory Council on Vaccination. Member of the Spanish Association of Vaccinology
Este artículo ha recibido
Información del artículo
Abstract

People with Down syndrome (DS) are especially infection-prone, particularly during childhood. The main reason is an association of DS with multifactorial primary immune deficiency. Many of these conditions are immunizable, but studies of vaccination and DS are few and do not include recent formulations. While awaiting remediation of this gap, the present state of knowledge is that available vaccines are safe and effective for people with DS, though the possibility that response may be lower than average means that strict compliance with immunization schedules is required to ensure effectiveness.

Keywords:
Down syndrome
Active immunization
Vaccination
Passive immunization
El Texto completo está disponible en PDF
Bibliography
[1.]
A. Martín-Mateos.
Inmunidad en el síndrome de Down.
Síndrome de Down. Aspectos médicos actuales, pp. 109-117
[2.]
L. Nespoli, G.R. Burgio, A.G. Ugazio, R. Maccario.
Immunological features of Down's syndrome: a review.
J Intel Disabil Res, 37 (1993), pp. 543-551
[3.]
Y.C.M. De Hingh, P.W. van der Vossen, E.F.A. Gemen, et al.
Intrinsic abnormalities of lymphocyte counts in children with Down Syndrome.
J Pediatr, 147 (2005), pp. 744-747
[4.]
B. Breuer, S.M. Friedman, E.S. Millner, et al.
Transmision of Hepatitis B virus to classroom contacts of mentally retarded carriers.
JAMA, 254 (1985), pp. 3190-3195
[5.]
M. García Bengoechea, J.J. Legarda, A. Cortés, et al.
Los deficientes mentales y la infección por el virus de la hepatitis B. Prevalencia en nuestro medio.
Med Clin (Barcelona), 93 (1989), pp. 10-13
[6.]
J. Arístegui-Fernández, R. Cisterna-Cáncer, J. Muñiz-Saitua, et al.
Prevalencia de infección por el virus de la hepatitis B en instituciones de deficientes mentales. Características epidemiológicas en la provincia de Vizcaya.
Med Clin (Barcelona), 92 (1989), pp. 323-327
[7.]
M.J. Rua-Armesto, V. Ramírez-Marín, M.T. Onaindia-Ercoreca, et al.
Predisposición del síndrome de Down a la infección crónica por el virus B de la hepatitis.
An Esp Pediatr, 38 (1993), pp. 529-531
[8.]
V. Di Ciommo, F. Ferrario, M. Rossi de Gasperi, et al.
Epidemiology of hepatitis B virus in non institutionalized children and adolescents affected by handicap.
J Intel Disabil Res, 37 (1993), pp. 295-299
[9.]
M. Wahl, S. Hermodason, S. Iwarson.
Immune response to hepatitis B vaccine in the mentally retarded.
J Infect, 7 (1983), pp. S47-S51
[10.]
O. García, M. Bruguera, J.M. Mayor, et al.
Hepatitis B en una institución abierta para retrasados mentales Efecto inmunogénico de una vacuna recombinante antihepatitis B.
Enf Inf Microbiol Clin, 8 (1990), pp. 148-152
[11.]
S. Krugman.
Hepatitis Bcarriers in the classroom (Editorial).
JAMA, 254 (1985), pp. 3218-3219
[12.]
M.A. Avanzini, V. Monafo, M. De Amici, et al.
Humoral immunodeficiencies in Down Syndrome: Serum IgG subclass and antibody response to hepatitis B vaccine (Letter to the Editor).
Am J Med Genet, (1990), pp. 231-233
[13.]
M. Piccione, M. De Curtis, M.L. La Vecchia, et al.
Hepatitis Band C infection in children with Down syndrome.
Eur J Pediatr, 156 (1997), pp. 420-421
[14.]
R. Ward, P. Borchert, A. Wright, E. Kline.
Hepatitis Bantigen in saliva and mouth washings.
Lancet, 2 (1972), pp. 726-727
[15.]
C.L. Troisi, D.A. Heiberg, F. Blaine Hollinger.
Normal immune response to Hepatitis B vaccine in patients with Down Syndrome. A basis for immunization guidelines.
JAMA, 254 (1985), pp. 3196-3199
[16.]
J. Cobo-Soriano, A. Gil-Miguel, J. Rey-Calero, et al.
Inmunogenicidad de la vacuna contra el VHB en deficientes mentales.
At Primaria, 8 (1991), pp. 536-541
[17.]
P. Van Damme, R. Vranckx, A. Meheus.
Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down's syndrome.
Vaccine, 8 (1990), pp. S53-S55
[18.]
M. García-Bengoechea, E. Cortés, J. Cabriada, et al.
Respuesta a la vacuna DNA recombinada antihepatitis B en los deficientes mentales con síndrome de Down. Estudio controlado.
Med Clin (Barcelona), 94 (1990), pp. 528-530
[19.]
P. Vajro, P. Letrera, A. Fontanella, et al.
Vaccination against hepatitis B in preschool children with Down's syndrome.
J Intel Disabil Res, 36 (1992), pp. 77-81
[20.]
M.A. Avanzini, T. Söderström, M. Wahl, et al.
IgG subclass deficiency in patients with Down's syndrome and aberrant hepatitis B vaccine response.
Scand J Immunol, 28 (1988), pp. 465-470
[21.]
J. Green.
Hepatitis Band Down's syndrome.
BMJ, 297 (1988), pp. 1336
[22.]
J.M. Corretger, R. Baraibar.
Vacunaciones en niños con enfermedades crónicas.
Vacunaciones en el niño. De la teoría a la práctica, pp. 880-882
[23.]
C.T. Ferreira, J.C. Leite, A. Taniguchi, et al.
Immunogenicity and safety of an inacivated hepatitis A vaccine in children with Down syndrome.
Pediatr Gastroenerol Nutr, 39 (2004), pp. 337-340
[24.]
M.M. Garrison, H. Jeffries, D.A. Christakis.
Risk of death for children with Down syndrome and sepsis.
J Pediatr, 147 (2005), pp. 748-752
[25.]
T. Nurmi, M. Leinonen, V.M. Haiva, et al.
Antibody response to pneumoccoccal vaccine in patients with trisomy-21 (Down's syndrome).
Clin Expo Immunol, 48 (1982), pp. 485-490
[26.]
B.T. Costa-Carvalho, R.M.A. Martinez, A.T.N. Dias, et al.
Antibody response to pneumococcal capsular vaccine in Down syndrome patients.
Braz J Med Res, 39 (2006), pp. 1587-1592
[27.]
R. Philip, A.C. Berger, N.H. McManus, et al.
Abnormalities of the in vitro cellular and humoral responses to tetanus and influenza antigens with concomitant numerical alterations in lymphocyte subsets in Down syndrome (trisomy 21).
J Immunol, 136 (1986), pp. 1661-1667
[28.]
M.G. Gordon, S.K. Sinha.
Antibody responses to influenza vaccine in patients with Down's syndrome.
Am J Ment Def, 75 (1971), pp. 391-399
[29.]
R.A. Hawkes, C.R. Boughton, D.R. Shroeter.
The antibody response of institutionalized Down's syndrome to seven microbial antigens.
Clin Exp Immunol, 31 (1978), pp. 298-304
[30.]
A.W. Griffiths, P.E. Sylvester.
Mongols and non-mongols compared in their response to active tetanus immunisation.
J Ment Def Res, 11 (1867), pp. 263-266
[31.]
S. LiVolti, T. Mattina, L. Mauro, et al.
Safety and effectiveness of an acellular pertussis vaccine in subjects with Down's syndrome.
Childs Nerv Syst, 12 (1996), pp. 100-102
[32.]
R.A. Hawkes, S.C. Philbrook.
The response of institutionalized Down's syndrome subjects to enterovirus infections.
J Hyg, 84 (1980), pp. 433-441
[33.]
B.L.P. Bloemers, M. van Furth, M.E. Weijerman, et al.
Down Syndrome: A novel risk factor for Respiratory Syncitial Virus bronchiolitis – A prospective Birth-Cohort study.
Pediatrics, 120 (2007), pp. 1076-1081
Copyright © 2008. Fundació Catalana Síndrome Down
Descargar PDF
Opciones de artículo